Literature DB >> 8876561

A modified, prolonged desensitization protocol in carboplatin allergy.

A Goldberg1, R Confino-Cohen, A Fishman, Y Beyth, M Altaras.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8876561     DOI： 10.1016/s0091-6749(96)70134-3

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

1.  Desensitization Protocol to Carboplatin: A Technical Report.

Authors:  Cornelia Nitipir; Andreea Parosanu; Ana Maria Popa; Horia Cotan; Mihaela Olaru; Cristian Iaciu; Cristina Orlov Slavu
Journal:  Cureus       Date:  2022-04-26

2.  Hypersensitivity reactions to carboplatin in children.

Authors:  Ilaria Lazzareschi; Antonio Ruggiero; Riccardo Riccardi; Giorgio Attinà; Cesare Colosimo; Anna Lasorella
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

3.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

Review 4.  Hypersensitivity reactions to chemotherapeutic drugs.

Authors:  Gillian M Shepherd
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

5.  Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.

Authors:  Maurie Markman; Fred Hsieh; Kristine Zanotti; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Ann Spicel; Jerome Belinson
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

6.  Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Authors:  J Boulanger; J N Boursiquot; G Cournoyer; J Lemieux; M S Masse; K Almanric; M P Guay
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

7.  Analysis of Breakthrough Reactions in 1,143 Desensitization Procedures in a Single Tertiary Hospital Using a One-Bag Desensitization Protocol.

Authors:  Hyun Hwa Kim; Jeongmin Seo; Yoon Hae Ahn; Hyunjee Kim; Jeong-Eun Yoon; Jang Ho Suh; Dong Yoon Kang; Suh Young Lee; Hye-Ryun Kang
Journal:  Front Allergy       Date:  2022-02-11

8.  A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.

Authors:  Yoichiro Yoshida; Keiji Hirata; Hiroshi Matsuoka; Shigeyoshi Iwamoto; Masahito Kotaka; Hideto Fujita; Naoya Aisu; Seiichiro Hoshino; Takeo Kosaka; Kotaro Maeda; Fumiaki Kiyomi; Yuichi Yamashita
Journal:  Drug Des Devel Ther       Date:  2015-11-11       Impact factor: 4.162

9.  Severe anaphylaxis caused by intravenous anti-cancer drugs.

Authors:  Nobuyuki Horita; Etsuko Miyagi; Taichi Mizushima; Maki Hagihara; Chiaki Hata; Yuki Hattori; Narihiko Hayashi; Kuniyasu Irie; Hideyuki Ishikawa; Yusuke Kawabata; Yosuke Kitani; Noritoshi Kobayashi; Nobuaki Kobayashi; Yusuke Kurita; Yohei Miyake; Kentaro Miyake; Senri Oguri; Ichiro Ota; Ayako Shimizu; Masanobu Takeuchi; Akimitsu Yamada; Kojiro Yamamoto; Norio Yukawa; Munetaka Masuda; Nobuhiko Oridate; Yasushi Ichikawa; Takeshi Kaneko
Journal:  Cancer Med       Date:  2021-09-10       Impact factor: 4.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.